• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

    8.205 +0.195 (+2.43%)
    Streaming Delayed Price Updated: 11:45 AM EDT, Jul 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 290,720
    Open 8.010
    Bid (Size) 8.200 (500)
    Ask (Size) 8.210 (600)
    Prev. Close 8.010
    Today's Range 7.970 - 8.215
    52wk Range 6.660 - 18.63
    Shares Outstanding 95,568,307
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
    From Pomerantz LLP
    Via GlobeNewswire

    Performance

    YTD
    -28.6%
    -28.6%
    1 Month
    -13.0%
    -13.0%
    3 Month
    +2.2%
    +2.2%
    6 Month
    -29.5%
    -29.5%
    1 Year
    -53.0%
    -53.0%

    More News

    Read More
    News headline image
    SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Thursday? ↗
    Via Chartmill
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    ARS Pharmaceuticals Provides Commercial and Financial Updates
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma (SPRY) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    ARS Pharma (SPRY) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    ARS Pharmaceuticals Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
    Via Benzinga
    News headline image
    ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
    Via The Motley Fool
    News headline image
    ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
    ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
    What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
    The current price of ARS Pharmaceuticals, Inc. - Common Stock is 8.205
    When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 07/01/26 11:45 AM ET
    What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 784.14M
    How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
    ARS Pharmaceuticals, Inc. - Common Stock has 784M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.